Industry News

Pieris Pharmaceuticals, Inc., a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for cancer and other diseases, announced today that Christopher Kiritsy has joined the Company's Board of Directors, bringing the total number of directors to seven. Kiritsy is a co-founder of Arisaph Pharmaceuticals, Inc. and has served as Arisaph's President and Chief Executive Officer..."/>
Pieris Pharmaceuticals Appoints Christopher Kiritsy to Its Board of Directors
Teladoc, Inc., the nation’ s leading provider of telehealth services, today announced that David Shedlarz, former vice chairman, executive vice president and chief financial officer of Pfizer Inc., has been appointed to its board of directors. This appointment comes on the heels of last quarter's board addition, Helen Darling, with both appointments responding to the need to support the rapidly expanding foothold Teladoc has secured in the evolving..."/>
Teladoc Appoints Former Pfizer Vice Chairman and CFO David Shedlarz to Board of Directors
Aurinia Pharmaceuticals Inc.,, a clinical stage biopharmaceutical company focused on the global immunology market, today announced that its Chief Executive Officer, Charles Rowland, will participate in a Fireside Chat at the Leerink Partners Roundtable Series: Rare Disease and Immuno-Oncology on September 28, 2016 at 11:05am ET in New York. To access the live webcast, please visit the investor section of the Aurinia website. A replay will also be..."/>
Aurinia Pharmaceuticals to Present at the Leerink Partners Roundtable Series in New York September 28, 2016
Enumeral Biomedical Holdings, Inc., a biotechnology company focused on the discovery and development of novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced that Wael Fayad has been appointed Chairman, President, and Chief Executive Officer of the Company, effective as of September 21, 2016.. Fayad brings to Enumeral more than two decades of senior executive and business development experience..."/>
Enumeral Appoints Wael Fayad as Chairman, President and Chief Executive Officer
AntriaBio, Inc., a biopharmaceutical corporation focused on developing novel extended release therapies, announced today that it is forming a new wholly owned subsidiary in Seoul, South Korea to focus on research and development as well as potential manufacturing opportunities. AntriaBio intends to simultaneously begin raising capital primarily from Korean institutional investors with a goal of closing the financing prior to the end of 2016. The..."/>
AntriaBio Announces Formation of Subsidiary and Plan to Raise Capital in South Korea
Depomed, Inc., a pharmaceutical company focused on commercializing drugs for central nervous system conditions including pain, announced its support of the American Chronic Pain Association's Toolkit for Healthcare Professionals: Activities and Resources as part of Pain Awareness Month, recognized in September. The toolkit provides a set of multi-disciplinary resources for primary care providers, including guidelines, templates..."/>
Depomed Supports the American Chronic Pain Association's Toolkit for Primary Care Providers
Allergan plc, a leading global pharmaceutical company, and Adamas Pharmaceuticals, Inc. announced today that all four dosage strengths of NAMZARIC ® extended-release capsules that allow patients on donepezil 10 mg to start directly on NAMZARIC are now available by prescription in pharmacies throughout the U.S. NAMZARIC is a once-daily, fixed-dose combination of memantine hydrochloride and donepezil hydrochloride..."/>
Allergan and Adamas Announce U.S. Availability of New Dosage Strengths for NAMZARIC® (Memantine and Donepezil Hydrochlorides) Extended Release for the Treatment of Moderate to Severe Alzheimer's Disease
Biostar Pharmaceuticals, Inc., a PRC-based manufacturer of pharmaceutical and health supplement products, and Xianyang Yongsheng Health Products Co., Ltd., a privately held PRC-based health product manufacturer located in Xianyang, China, announced today that they have entered into a non-binding Letter of Intent under which Biostar intends to acquire 100% of equity interest in Xianyang Yongsheng in exchange for a cash payment, the..."/>
Biostar Pharmaceuticals Signs a Letter of Intent to Acquire Xianyang Yongsheng Health Products Co., Ltd.
CANTEL MEDICAL CORP. will release the results for its fourth quarter and fiscal year ended July 31, 2016 on Thursday, September 29 before the market opens, and hold a conference call to discuss the results at 11:00 AM ET. To participate in the conference call, dial 1-877-407-8033 or 1-201-689-8033 approximately 5 to 10 minutes before the beginning of the call. If you are unable to participate, a digital replay of the call will be available..."/>
Cantel Medical Corp. to Hold Conference Call to Discuss Results for its Fourth Quarter and Fiscal Year Ended July 31, 2016
Relmada Therapeutics, Inc., a clinical-stage company developing novel therapies for the treatment of central nervous system diseases, today announced that the Company will present at the 2016 Ladenburg Thalmann Healthcare Conference being held September 27, 2016 at the Sofitel Hotel in New York City. The presentation by Sergio Traversa, Chief Executive Officer of Relmada Therapeutics, is scheduled to begin at 2:00 p.m. Eastern Time on..."/>
Relmada Therapeutics to Present at the Ladenburg Thalmann 2016 Healthcare Conference
Charles River Laboratories International, Inc. today announced that it has entered into a strategic partnership agreement with The Tri-Institutional Therapeutics Discovery Institute, intended to accelerate the development of therapeutics that arise from discoveries made in Tri-I TDI’ s academic labs. Tri-I TDI is a cooperative endeavor of Memorial..."/>
Charles River Laboratories and The Tri-Insitutional Therapeutics Discovery Institute Announce Strategic Partnership
Impax Laboratories, Inc. today announced the launch of a generic version of Metadate CD ®, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, and 60 mg. Impax is focused on further enhancing its portfolio of 73 solid oral dose and alternative dosage form generic products available. The launch of methylphenidate hydrochloride is Impax's sixth new product launch since the beginning of 2016.."/>
Impax Launches Generic Version of Metadate CD® (Methylphenidate Hydrochloride Extended-Release Capsules)
Teva Pharmaceutical Industries Ltd. today announced SD-809 showed statistically significant results in the second Phase III registration trial studying the potential of SD-809 for the treatment of tardive dyskinesia."/>
Teva Announces Positive Top-Line Data from Second Phase III Study of SD-809 in Tardive Dyskinesia (TD)
Inovalon, a leading technology company providing advanced, cloud-based analytics and data-driven intervention platforms to the healthcare industry, has entered into a definitive agreement to acquire Creehan Holding Co., Inc., the parent company of Creehan& Company, the industry’ s leading independent provider of specialty pharmacy and specialty medications management software-as-a-service platforms.. “Specialty pharmacy is a uniquely high-value..."/>
Inovalon To Acquire Creehan & Company, Industry-Leading Specialty Pharmacy SaaS Platform
BIOLASE reported on Wednesday that it has appointed Holger Arens as vice president and managing director for Europe, the Middle East and Africa effective immediately. Based in Germany, Arens will oversee all of the company's EMEA commercial and operational activities and will report directly to president and CEO Harold C. Flynn, Jr. Since 2013, Arens has been consulting with dental and medical technology entrepreneurs, investors and manufacturers in..."/>
BIOLASE appoints Holger Arens as VP and MD for EMEA
Amicus Therapeutics, a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a corporate overview and fireside chat at the LEERINK Partners Roundtable Series: Rare Disease& Immuno-Oncology in New York, NY on September 28, 2016 at 3:05pm ET.. An audio webcast of the presentation can be accessed through the Investors section..."/>
Amicus Therapeutics to Present at LEERINK Roundtable Series: Rare Disease & Immuno-Oncology
Proteostasis Therapeutics, Inc., a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing, such as cystic fibrosis, today announced that company scientists will present data from its ongoing Phase 1 clinical trials studying PTI-428 in subjects with CF and healthy volunteers at the 30 th Annual North American Cystic Fibrosis Conference. In addition, Proteostasis..."/>
Proteostasis Therapeutics Announces Scientific Presentations on New Data at 30th Annual North American Cystic Fibrosis Conference
Transgenomic, Inc.,, today announced that it has signed a data sharing agreement with Ventana Medical Systems, Inc., a subsidiary of Roche Holdings. The agreement allows Ventana to access DNA test results from an existing research agreement between Transgenomic and the University of Melbourne in Australia. As part of this research agreement, the University of Melbourne is conducting additional clinical validation studies of Transgenomic’ s Multiplexed ICE..."/>
Transgenomic and Ventana Medical Systems Complete Data Sharing Agreement
Portola Pharmaceuticals Inc., bluebird bio Inc., Auris Medical Holding A.G., and Cerulean Pharma Inc.. Yesterday, the markets were on a bullish course with all indices in the green."/>
Biotech Stocks on Investors' Radar -- Portola Pharma, bluebird bio, Auris Medical, and Cerulean Pharma
Xenetic Biosciences, Inc., a biopharmaceutical company developing next-generation biologic drugs and novel orphan oncology therapeutics, today announced that Scott Maguire, CEO of Xenetic Biosciences, will present at the Ladenburg Thalmann 2016 Healthcare Conference on Tuesday, September 27, 2016 at 3:30 p.m. ET in New York at the Sofitel New York. Maguire will provide a..."/>
Xenetic Biosciences to Present at the Ladenburg Thalmann 2016 Healthcare Conference
NeuroMetrix, Inc. announced today that Synovation Medical Group will conduct an evaluation of Quell ® Wearable Pain Relief Technology™ in fibromyalgia patients. "We have seen both clinical data and positive reviews that suggest that Quell may be beneficial in reducing pain and improving the quality of life in people who suffer from fibromyalgia," said Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix. "This clinical evaluation will provide additional..."/>
NeuroMetrix Announces Quell Fibromyalgia Pilot with Synovation Medical Group
Natus Medical Incorporated today announced the appointment of Barbara R. Paul, M.D. to its board of directors.. "We are pleased to have Dr. Paul join the Natus Board of Directors, "said Robert Gunst, chairman of Natus' board of directors."/>
Natus Medical Announces Appointment of Barbara R. Paul, M.D. to its Board of Directors
Antares Pharma, Inc. today announced safety results from the dose-blinded, multiple-dose, concentration-controlled, 26- week phase 3 study of QuickShot ® Testosterone administered subcutaneously once each week to adult males with hypogonadism. The study, QST-15-005, included a screening phase, a titration phase and a treatment phase for evaluation of safety and tolerability, including laboratory assessments, adverse events and injection site..."/>
Antares Pharma Announces Completion of the QuickShot Testosterone Clinical Program
Anavex Life Sciences Corp. today presented preclinical data demonstrating that ANAVEX 2-73, a sigma-1 receptor agonist, restores function in a classic animal model of Parkinson’ s disease. Significant improvements were seen on all measures: behavioral, histopathological, and neuroinflammatory endpoints.. Veronica Francardo, PhD, and Angela Cenci, PhD, main authors of the study at Lund University, Sweden, commented:“ We are in the fortunate situation that..."/>
Anavex Life Sciences’ Drug Shows Efficacy to Support Potential Disease Modification in Parkinson’s Disease

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology511 Articles
Consumer Discretionary507 Articles
Financials322 Articles
Industrials306 Articles
Health Care291 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at